Alpha 2.0
Login Register
» Authors » Kosuke Hamai

Kosuke Hamai

Explore the profile of Kosuke Hamai including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 29
Citations 161
Followers 0
Related Specialties
Oncology
Pulmonary Medicine
General Medicine
Top 10 Co-Authors
Nobuhisa Ishikawa
Kazunori Fujitaka
Noboru Hattori
Takeshi Masuda
Sayaka Ueno
Takuya Tanimoto
Masahiro Yamasaki
Hiroshi Iwamoto
Mirai Matsumura
Yukari Tsubata
Published In
Respir Investig
Geriatr Gerontol Int
Thorac Cancer
Intern Med
Cancer Rep (Hoboken)
Affiliations
Soon will be listed here.
Recent Articles
1.
Influenza A Infection With Virus-Associated Pneumonia and Hemorrhagic Shock and Encephalopathy Syndrome in an Adult
Nakanishi Y, Tanimoto N, Tsuyuki M, Une K, Hamai K
Cureus . 2024 Dec; 16(11):e72820. PMID: 39618746
Hemorrhagic shock and encephalopathy syndrome (HSES) is a subtype of influenza-associated encephalopathy (IAE) and primarily occurs in infants. It presents with high fever, disorder of consciousness, convulsions, and shock, which...
2.
A Case of Anti-OJ Antibody-positive Antisynthetase Myopathy Diagnosed after Pulmonary Embolization
Nakanishi Y, Watanabe H, Tsuyuki Y, Tsuyuki M, Kakumoto S, Abe M, et al.
Intern Med . 2024 Nov; PMID: 39523002
Idiopathic inflammatory myopathies, such as dermatomyositis, are implicated as possible risk factors for venous thromboembolism. We herein report the first known case of a 50-year-old woman who presented to our...
3.
Comparison of efficacy of gefitinib and osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer in patients with poor performance status
Nakashima K, Kodama H, Murakami H, Takahashi T, Kawakado K, Yanagawa T, et al.
Respir Investig . 2024 Oct; 62(6):1137-1141. PMID: 39366122
Background: There is a dearth of studies on the efficacy and safety of the tyrosine kinase inhibitors osimertinib (OSI) and gefitinib (GEF) in treating epidermal growth factor receptor (EGFR) mutation-positive...
4.
Impact of Cachexia and First-Line Systemic Therapy for Previously Untreated Advanced Non-Small Cell Lung Cancer: NEJ050A
Miura K, Shukuya T, Furuya N, Morita R, Kisohara A, Mouri A, et al.
J Cachexia Sarcopenia Muscle . 2024 Oct; 15(6):2618-2628. PMID: 39351653
Background: Cancer cachexia complicates advanced non-small cell lung cancer (NSCLC); however, it remains unclear how often cachexia occurs and how it affects the course of chemotherapy in patients receiving first-line...
5.
A Retrospective Analysis of the Efficacy of Oral Dexamethasone in Combination With Docetaxel Plus Ramucirumab Therapy for Previously Treated Lung Cancer
Hamai K, Katsura R, Miyake S, Fujita S, Tada S, Hirakawa T, et al.
Cancer Control . 2024 Aug; 31:10732748241274615. PMID: 39120923
Introduction: Docetaxel plus ramucirumab (DTX + RAM) therapy is a standard treatment for previously treated lung cancer, but many adverse events have been reported. This retrospective study was conducted to...
6.
Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer
Masuda T, Miura S, Sato Y, Tachihara M, Bessho A, Nakamura A, et al.
Sci Rep . 2023 Nov; 13(1):19729. PMID: 37957228
Small amounts of epidermal growth factor receptor (EGFR) T790M mutation (micro-T790M), which is detected using droplet digital PCR (ddPCR) but not conventional PCR, in formalin-fixed and paraffin-embedded (FFPE) samples have...
7.
Comprehensive genomic profiling of Japanese patients with thoracic malignancies: A single-center retrospective study
Hirakawa T, Doi M, Hamai K, Katsura R, Miyake S, Fujita S, et al.
Respir Investig . 2023 Sep; 61(6):746-754. PMID: 37714093
Background: Few studies have been conducted on comprehensive genomic profiling (CGP) panels in Japanese patients with thoracic malignancies after completing standard treatment. Consequently, its value in clinical practice remains unclear....
8.
Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer
Hamai K, Miyaka S, Tada S, Fujita S, Hirakawa T, Matsumura M, et al.
Cancer Rep (Hoboken) . 2023 Feb; 6(4):e1793. PMID: 36727271
Background: Pegfilgrastim is recommended in docetaxel plus ramucirumab (DTX + RAM) therapy for recurrent nonsmall cell lung cancer (NSCLC) because of the associated frequency of febrile neutropenia (FN). However, the...
9.
Pre-Existing Interstitial Lung Abnormalities Are Independent Risk Factors for Interstitial Lung Disease during Durvalumab Treatment after Chemoradiotherapy in Patients with Locally Advanced Non-Small-Cell Lung Cancer
Daido W, Masuda T, Imano N, Matsumoto N, Hamai K, Iwamoto Y, et al.
Cancers (Basel) . 2022 Dec; 14(24). PMID: 36551721
Introduction/Background: Chemoradiotherapy (CRT) followed by durvalumab, an immune checkpoint inhibitor, is the standard treatment for locally advanced non-small-cell lung cancer (NSCLC). Interstitial lung disease (ILD) is a life-threatening toxicity caused...
10.
Identification of risk factors for venous thromboembolism and validation of the Khorana score in patients with advanced lung cancer: based on the multicenter, prospective Rising-VTE/NEJ037 study data
Tsubata Y, Kawakado K, Hamai K, Furuya N, Yokoyama T, Saito R, et al.
Int J Clin Oncol . 2022 Nov; 28(1):69-78. PMID: 36357710
Background: Management of cancer-associated venous thromboembolism (VTE) is essential in cancer treatment selection and prognosis. However, currently, no method exists for assessing VTE risk associated with advanced lung cancer. Therefore,...